Wall Street Transcript Interview with Thomas M. Patton, President and CEO of CAS Medical Systems, Inc. (CASM)

Wall Street Transcript

67 WALL STREET, New York - August 2, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act - Continued Pricing Pressure - Aging U.S. Population

Companies include: CAS Medical Systems Inc. (CASM) and many more.

In the following excerpt from the Medical Devices Report, the President and CEO of CAS Medical Systems, Inc. (CASM) discusses company strategy and the outlook for this vital industry:

TWST: What is CASMED?

Mr. Patton: CAS Medical Systems, ticker CASM, is a microcap medical products company in Branford, Connecticut, that's been around since the 1980s developing high-quality patient monitoring equipment. We sell a number of different products, but chief among them is a fascinating technology that measures the oxygenation of the tissue of the brain during surgery or other episodes of patient critical care. That product is our FORE-SIGHT brand of cerebral oximeters, and it can detect dangerously low levels of oxygen in the brain that would otherwise go undetected without this direct method of monitoring.

In addition to FORE-SIGHT, we sell a series of vital signs monitors under the brand 740 SELECT, for lower acuity patient care, and we have a noninvasive blood pressure technology that we sell to other manufacturers who then incorporate that technology into their own monitors. New versions of all three products, with state-of-the-art features and design, are being introduced this quarter.

TWST: Speaking about your FORE-SIGHT ELITE Oximeter and the 740 SELECT; can you tell us about the market size for these products and the possible penetration?

Mr. Patton: We think the current market size for cerebral oximetry worldwide is approximately $80 million, but that only represents about 35% penetration of the primary cardiac heart surgeries and low levels of penetration for many other applications and procedures. Considering all its applications, we think the total addressable market for cerebral oximetry is $400 million or more. With FORE-SIGHT, including our new FORE-SIGHT ELITE monitor that will be introduced this quarter, we believe CASMED is uniquely positioned to both gain market share from competitors and drive further market penetration.

The market segment for vital signs monitors is approximately $250 million. Our new 740 SELECT, which also should be released this quarter, replaces a very successful 10-year-old product line that has seen worldwide sales of over 20,000 monitors. Building on that brand value, we believe the 740 SELECT will enable us to...

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

View Comments (0)